Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Conditions:   High Grade Glioma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Glioblastoma Interventions:   Drug: Regadenoson 0.05mg;   Drug: Regadensoson 0.1mg;   Drug: Regadensoson 0.2mg;   Drug: Regadensoson 0.4mg;   Drug: Regadensoson 0.7mg;   Drug: Regadensoson 1.0mg;   Drug: Regadensoson 1.4mg Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials